Nektar Therapeutics

NKTR 
(NASDAQ) 
 
$ 20.15 <%= Resources.Global.txtDown %>
Updated 19/09/2019
Change % -0.35% Stock price decreasing
Change -0.07 Stock price decreasing
Volume 4,213,629
High $ 20.76
Low $ 20.02
Open $ 20.24
ISIN
Prev close $ 20.22
# of shares 175.27M
Market cap 3,531.78M USD
Intraday

Market closed
Nektar Therapeutics
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  20.15 0.2% Stock price increasing 18.5% Stock price increasing -42.2% Stock price decreasing -39.8% Stock price decreasing -65.8% Stock price decreasing
Powered by TradingView

News about Nektar Therapeutics

  • English
  • Regulatory news

Company profile

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 September 2019 00:22:23
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB5 - 2019-09-21 01:22:23 - 2019-09-21 00:22:23 - 1000 - Website: OKAY